A field of Ozempic at a pharmacy in Los Angeles on Aug. 6, 2025.

Eric Thayer/Bloomberg through Getty Photographs

conceal caption

toggle caption

Eric Thayer/Bloomberg through Getty Photographs

The federal authorities has introduced the outcomes of the newest spherical of Medicare drug value negotiations: 15 decrease drug costs for Medicare to enter impact in 2027.

Medicare will get a 71% low cost on Ozempic, Wegovy and Rybelsus, blockbuster medication for weight problems and Sort 2 diabetes which have present listing costs of round a thousand {dollars} a month.

The negotiations additionally included medication for bronchial asthma, breast most cancers and leukemia. The reductions ranged from 38% for Austedo, which treats Huntington’s illness, to 85% for Janumet for Sort 2 diabetes.

“President Trump directed us to cease at nothing to decrease well being care prices for the American individuals,” stated Well being and Human Companies Secretary Robert F. Kennedy, Jr., in a press launch. “As we work to Make America Wholesome Once more, we’ll use each software at our disposal to ship reasonably priced well being care to seniors.”

This system that covers medication for greater than 50 million seniors negotiated its first batch of drug costs final yr, after the passage of the Biden-era Inflation Discount Act in 2022.

A provision of that regulation, handed with out Republican help, ended Medicare’s 20-year ban on negotiating drug costs.

Negotiations for this second batch of 15 medication wrapped up on the finish of October.

The Facilities for Medicare and Medicaid Companies (CMS) say the brand new, decrease Medicare costs would have saved this system $12 billion {dollars} if the decrease negotiated costs had been in impact in 2024.

The newest negotiated costs are nice information for taxpayers and sufferers, says Dr. Benjamin Rome, well being coverage researcher at Brigham and Girls’s Hospital in Boston. Federal taxpayers fund a lot of Medicare, however beneficiaries additionally should pay copays and coinsurance.

“That is extra financial savings than the primary spherical, however quite a lot of that has to do with the character of the medication being negotiated this yr and doubtless some studying from expertise,” he says.

Medication had been chosen earlier this yr based mostly on standards written into the regulation. They needed to don’t have any generic or biosimilar competitors, account for a excessive quantity of Medicare spending and be available on the market for a lot of years.

The decrease Ozempic and Wegovy costs observe a separate deal the Trump administration introduced on Nov. 6 with Novo Nordisk, which makes each medication.

That deal was a part of the president’s push to get drug corporations to voluntarily decrease their U.S. costs to match these in different developed nations.

However, confusingly, the reductions from the Medicare negotiations had been much less important than what Novo Nordisk agreed to offer Medicare as a part of the Nov. 6 deal.

That earlier deal set a value of $245 {dollars} a month for Ozempic and Wegovy. However in line with the negotiated costs introduced this week, the costs of Ozempic, Wegovy and Rybelsus — the corporate’s Sort 2 diabetes tablet — will likely be $274 a month.

“It is not clear why Novo [Nordisk] would promise a special value in two completely different venues,” Rome says.

In an organization assertion, Novo Nordisk defined that it “look[s] ahead to further readability from CMS on how pricing and protection will work.”

The separate Trump Administration deal “displays a broader effort to broaden entry to weight problems care throughout Medicare and Medicaid,” the assertion stated.

(The deal expanded entry in these two packages to the medication to individuals with a physique mass index of over 35 and folks with BMIs above 27 who’ve further well being situations. However the particulars of precisely how this can work stay unclear.)

The Novo Nordisk assertion affirmed that the corporate is dedicated to advocating for reasonably priced entry to its medicines, however “we proceed to have severe issues concerning the Inflation Discount Act’s affect on sufferers and stay against authorities value setting.”

AARP, an advocacy group for the 125 million People who’re 50 and older, was happy with the outcomes of the negotiations.

“As we speak’s announcement marks one more important subsequent step ahead in our long-standing efforts to decrease prescription drug costs,” AARP’s CEO Dr. Myechia Minter-Jordan stated in a press release.

“Older People throughout the political spectrum constantly say decrease drug costs are a high precedence, and these negotiated costs will convey significant reduction to thousands and thousands of individuals on Medicare.”